Search research articles
Contact Us
Filters
Showing results (61-70 of 271) with videos related to
Page
of 28
Sort By:
Nature Reviews. Clinical Oncology
|
April 1, 2016
Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease
Xavier M Keutgen, Pascal Hammel, Peter L Choyke, et al.
Clinical Genitourinary Cancer
|
October 1, 2011
Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma
George E Manoukian, Nizar M Tannir, Eric Jonasch, et al.
The Journal of Urology
|
September 11, 2013
Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules
Bradley J Atkinson, Sarathi Kalra, Xuemei Wang, et al.
Cancer Treatment Reviews
|
July 14, 2020
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care
Daniel Castellano, Jose Pablo Maroto, Fawzi Benzaghou, et al.
Clinical Genitourinary Cancer
|
February 26, 2014
Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience
Aditya V Shetty, Marc R Matrana, Bradley J Atkinson, et al.
Palliative & Supportive Care
|
March 7, 2017
Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma
Isabel Leal, Kathrin Milbury, Joan Engebretson, et al.
Molecular Cancer Research : MCR
|
February 2, 2019
Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia
Yangsook Song Green, Timothy Sargis, Ethan Conrad Reichert, et al.
British Journal of Cancer
|
June 27, 2020
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events
Viktor Grünwald, Martin H Voss, Brian I Rini, et al.
The Journal of Urology
|
May 20, 2008
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma
Vitaly Margulis, Surena F Matin, Nizar Tannir, et al.
Clinical Genitourinary Cancer
|
August 24, 2019
Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma
Elshad Hasanov, Rebecca S S Tidwell, Pablo Fernandez, et al.
Page
of 28
Search research articles
Search
Showing results (61-70 of 271) with videos related to
Sort By:
Page
of 28
Nature Reviews. Clinical Oncology
|
April 1, 2016
Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease
Xavier M Keutgen, Pascal Hammel, Peter L Choyke, et al.
Clinical Genitourinary Cancer
|
October 1, 2011
Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma
George E Manoukian, Nizar M Tannir, Eric Jonasch, et al.
The Journal of Urology
|
September 11, 2013
Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules
Bradley J Atkinson, Sarathi Kalra, Xuemei Wang, et al.
Cancer Treatment Reviews
|
July 14, 2020
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care
Daniel Castellano, Jose Pablo Maroto, Fawzi Benzaghou, et al.
Clinical Genitourinary Cancer
|
February 26, 2014
Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience
Aditya V Shetty, Marc R Matrana, Bradley J Atkinson, et al.
Palliative & Supportive Care
|
March 7, 2017
Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma
Isabel Leal, Kathrin Milbury, Joan Engebretson, et al.
Molecular Cancer Research : MCR
|
February 2, 2019
Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia
Yangsook Song Green, Timothy Sargis, Ethan Conrad Reichert, et al.
British Journal of Cancer
|
June 27, 2020
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events
Viktor Grünwald, Martin H Voss, Brian I Rini, et al.
The Journal of Urology
|
May 20, 2008
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma
Vitaly Margulis, Surena F Matin, Nizar Tannir, et al.
Clinical Genitourinary Cancer
|
August 24, 2019
Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma
Elshad Hasanov, Rebecca S S Tidwell, Pablo Fernandez, et al.
Page
of 28